These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 26589235

  • 1. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
    Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK, GRAID investigators.
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of rituximab treatment for neuromyelitis optica.
    Fernández-Megía MJ, Casanova-Estruch B, Pérez-Miralles F, Ruiz-Ramos J, Alcalá-Vicente C, Poveda-Andrés JL.
    Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
    [Abstract] [Full Text] [Related]

  • 3. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopoulos DS, Evdokimidis I, Kilidireas C.
    J Neurol Sci; 2017 Jan 15; 372():92-96. PubMed ID: 28017256
    [Abstract] [Full Text] [Related]

  • 4. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
    Maillart E, Lippi A, Lubetzki C, Louapre C, Papeix C.
    Mult Scler Relat Disord; 2018 Feb 15; 20():220-222. PubMed ID: 29433095
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
    D'Amico E, Zanghì A, Chisari CG, Fermo SL, Toscano S, Arena S, Patti F, Zappia M.
    Mult Scler Relat Disord; 2019 Jan 15; 27():324-326. PubMed ID: 30471585
    [Abstract] [Full Text] [Related]

  • 6. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    Annovazzi P, Capobianco M, Moiola L, Patti F, Frau J, Uccelli A, Centonze D, Perini P, Tortorella C, Prosperini L, Lus G, Fuiani A, Falcini M, Martinelli V, Comi G, Ghezzi A.
    J Neurol; 2016 Sep 15; 263(9):1727-35. PubMed ID: 27286847
    [Abstract] [Full Text] [Related]

  • 7. Rituximab use in pediatric central demyelinating disease.
    Beres SJ, Graves J, Waubant E.
    Pediatr Neurol; 2014 Jul 15; 51(1):114-8. PubMed ID: 24768216
    [Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
    Alldredge B, Jordan A, Imitola J, Racke MK.
    Clin Neuropharmacol; 2018 Jul 15; 41(2):56-59. PubMed ID: 29389745
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of the treatment of neuromyelitis optica.
    Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N.
    J Neurol Sci; 2015 Apr 15; 351(1-2):31-35. PubMed ID: 25727350
    [Abstract] [Full Text] [Related]

  • 11. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, Smadja D, Marignier R, Francophone Society of Multiple Sclerosis and OFSEP investigators.
    J Neurol; 2018 Apr 15; 265(4):917-925. PubMed ID: 29455361
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.
    JAMA Neurol; 2013 Sep 01; 70(9):1110-7. PubMed ID: 23897062
    [Abstract] [Full Text] [Related]

  • 15. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA.
    Arch Neurol; 2008 Nov 01; 65(11):1443-8. PubMed ID: 18779415
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
    Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T.
    Mult Scler; 2009 Aug 01; 15(8):1006-8. PubMed ID: 19667025
    [Abstract] [Full Text] [Related]

  • 18. Serious safety events in rituximab-treated multiple sclerosis and related disorders.
    Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I.
    Ann Clin Transl Neurol; 2020 Sep 01; 7(9):1477-1487. PubMed ID: 32767531
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.